KR20010033017A - 과지질혈증 치료제인 스타틴-ＬＰ(ａ) 억제제의 병용 제제 - Google Patents

과지질혈증 치료제인 스타틴-ＬＰ(ａ) 억제제의 병용 제제 Download PDF

Info

Publication number
KR20010033017A
KR20010033017A KR1020007006370A KR20007006370A KR20010033017A KR 20010033017 A KR20010033017 A KR 20010033017A KR 1020007006370 A KR1020007006370 A KR 1020007006370A KR 20007006370 A KR20007006370 A KR 20007006370A KR 20010033017 A KR20010033017 A KR 20010033017A
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
statin
kit
pharmaceutical composition
acceptable salt
Prior art date
Application number
KR1020007006370A
Other languages
English (en)
Korean (ko)
Inventor
챨스 래리 비스게이어
로저 쇼필드 뉴턴
랜디 란지 람해락
Original Assignee
로즈 암스트롱, 크리스틴 에이. 트러트웨인
워너-램버트 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 로즈 암스트롱, 크리스틴 에이. 트러트웨인, 워너-램버트 캄파니 filed Critical 로즈 암스트롱, 크리스틴 에이. 트러트웨인
Publication of KR20010033017A publication Critical patent/KR20010033017A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020007006370A 1997-12-12 1998-11-04 과지질혈증 치료제인 스타틴-ＬＰ(ａ) 억제제의 병용 제제 KR20010033017A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6943297P 1997-12-12 1997-12-12
US60/069,432 1997-12-12
PCT/US1998/023480 WO1999030706A1 (en) 1997-12-12 1998-11-04 ANTIHYPERLIPIDEMIC STATIN-LP(a) INHIBITOR COMBINATIONS

Publications (1)

Publication Number Publication Date
KR20010033017A true KR20010033017A (ko) 2001-04-25

Family

ID=22088939

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020007006370A KR20010033017A (ko) 1997-12-12 1998-11-04 과지질혈증 치료제인 스타틴-ＬＰ(ａ) 억제제의 병용 제제

Country Status (14)

Country Link
EP (1) EP1037623A1 (ja)
JP (1) JP2003524582A (ja)
KR (1) KR20010033017A (ja)
AU (2) AU1306099A (ja)
BR (1) BR9813539A (ja)
CA (1) CA2299397A1 (ja)
HU (1) HUP0100349A3 (ja)
IL (1) IL134364A0 (ja)
IS (1) IS5385A (ja)
NO (1) NO20002965L (ja)
NZ (1) NZ502874A (ja)
PL (1) PL343851A1 (ja)
WO (1) WO1999030706A1 (ja)
ZA (1) ZA9811349B (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE304864T1 (de) 1997-01-07 2005-10-15 Amylin Pharmaceuticals Inc Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
EP1076091A1 (en) * 1999-08-09 2001-02-14 Universite Catholique De Louvain Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds
PT1246638E (pt) * 2000-01-10 2004-12-31 Amylin Pharmaceuticals Inc Utilizacao de exendinas e seus agonistas para o tratamento da ipertrigliceridemia
US20030018040A1 (en) * 2000-02-10 2003-01-23 Yasuo Sugiyama Tnf-alpha inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2016467A1 (en) * 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
WO1993013801A1 (en) * 1992-01-17 1993-07-22 The Procter & Gamble Company Treatment for atherosclerosis
CA2129732A1 (en) * 1992-02-25 1993-09-02 Alain Martin Cytoprotective compositions containing pyruvate and antioxidants
US5720963A (en) * 1994-08-26 1998-02-24 Mary Kay Inc. Barrier disruption treatments for structurally deteriorated skin
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
EP0738510A3 (fr) * 1995-04-20 2005-12-21 L'oreal Utilisation d'un inhibiteur d'HMG-coenzyme A-reductase pour lutter contre le vieillissement de la peau et pour traiter l'acné. Composition comprenant au moins un inhibiteur HMG-coenzyme A reductase et au moins un actif possédant des propriétes desquamantes
EP0904082A4 (en) * 1996-04-17 2001-09-26 Merck & Co Inc COMBINATION THERAPY TO REDUCE THE RISKS OF HEART CIRCULAR DISEASES
NZ503982A (en) * 1997-12-12 2002-03-28 Warner Lambert Co Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus

Also Published As

Publication number Publication date
NO20002965D0 (no) 2000-06-09
HUP0100349A3 (en) 2002-02-28
NO20002965L (no) 2000-06-09
NZ502874A (en) 2004-03-26
PL343851A1 (en) 2001-09-10
JP2003524582A (ja) 2003-08-19
EP1037623A1 (en) 2000-09-27
WO1999030706A1 (en) 1999-06-24
IL134364A0 (en) 2001-04-30
AU1306099A (en) 1999-07-05
ZA9811349B (en) 1999-06-14
AU2003244047A1 (en) 2003-09-25
HUP0100349A2 (hu) 2001-07-30
IS5385A (is) 2000-02-25
CA2299397A1 (en) 1999-06-24
BR9813539A (pt) 2000-10-10

Similar Documents

Publication Publication Date Title
AU744982B2 (en) Combination therapy comprising amlodipine and a statin compound
JP2004210797A (ja) アムロジピン及びアトルバスタチンを含む治療用の組み合わせ
UA56363C2 (uk) Спільна сіль амлодипіну та аторвастатину, фармацевтична композиція та спосіб лікування (варіанти)
EP1045691B1 (en) Statin-carboxyalkylether combinations
US20140012042A1 (en) Calcium Dicarboxylate Ethers
KR20010033017A (ko) 과지질혈증 치료제인 스타틴-ＬＰ(ａ) 억제제의 병용 제제
EP1280522B1 (en) Combination of carboxyalkylethers with antihypertensives and pharmaceutical use
US20020103252A1 (en) Statin-carboxyalkylether combinations
US20040092574A1 (en) Statin-Lp(a) inhibitor combinations
MXPA00002105A (en) Antihyperlipidemic statin-lp(a) inhibitor combinations
MXPA00002104A (en) Carton with panel locking means
EP1481962A1 (en) New cholesterolemia-lowering carboxyalkylether compound
MXPA00002085A (en) Combination therapy comprising amlodipine and a statin compound

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application